Molecule Life Cycle Management: POM to P to GSL - Switching Patients to Consumers 2011

March 10, 2011 - PRLog -- The considerable decline in the number of approved POM-P switches in recent years, despite early success highlights the need to address the issue. SMi Group provides a CPD accredited masterclass which helps those who want to find out more about making the switch from POM-P and P-GSL and enables industry professionals to discuss the challenges and develop strategies for them.

This event covers a broad range of topics and provides a comprehensive survey and in-depth analysis of the history of POM-P switches, switches that have failed and succeeded and the lessons that can be learnt from those successes and failures. The masterclass is headed by an expert, Alan Hicks, who has in-depth knowledge and experience in the pharmaceutical industry, who has created Janssen OTC Division which oversaw the launch of the first ever POM to P switch Imodium OTC.  By 1991 Janssen had also switched three other molecules in the therapy areas of hayfever, threadworm and thrush accounting for more than 50% of all switches at that time. In 1992 he left Janssen as Sales and Marketing Director responsible for both the prescription and OTC businesses, to set up his own company AHA offering POM to P expertise to the Pharmaceutical Industry.

Understanding why the numbers of POM-P switches have fallen and how to address the balance is all the more necessary as NHS spending cuts take effect which may potentially lead GPs to reduce prescribing and further promote self-care.  The masterclass will explore various case studies to ensure that lessons can be learned from past successes and failures.  

Benefits of attending SMi’s CPD accredited masterclass, Molecule Life Cycle Management: POM to P to GSL - Switching Patients to Consumers 2011:

Upon completion of this Masterclass, through a combination of presentations and interactive discussion, you will:

•Acquire an understanding of the current legalisation and
•Gain an insight from previous unsuccessful POM-P switches and how to avoid their pitfalls
•Examine the changing regulatory switch environment
•Discuss the lessons learned for future switching
•Assess the business model of the POM-P process
•Learn from an extremely experienced industry professional with over three decades of pharmaceutical experience.

For further information and the opportunity to register online please visit; http://www.smi-online.co.uk/1pom-p6.asp